Pablo Feuillet, MD
Infectious Disease · San Antonio, TXNPI 1922052570
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Melinta Therapeutics, LLC at 47.8% of the total. Reporting peaked in 2019 at $6,832 and has fallen 95.9% since, to $279 in 2025.
Across 132 payments — averaging $72.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$5K
- AbbVie$2K
- Cipla USA Inc.$1K
- Viiv Healthcare Company$566
- Merck$316
- Cumberland Pharmaceuticals, Inc.$174
- plus $673 from 11 others
What the payments were for
- Speaking & faculty fees$5,15054%
- Food & beverage$4,38246%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 30 | $4,562 |
| AbbVie(2 entities) | 21 | $1,816 |
| Cipla USA Inc. | 9 | $1,439 |
| Viiv Healthcare Company | 23 | $566 |
| Merck | 20 | $316 |
| Cumberland Pharmaceuticals, Inc. | 18 | $174 |
| Atricure, Inc. | 1 | $156 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $123 |
| Teva Pharmaceuticals USA, Inc. | 1 | $117 |
| Astellas Pharma US Inc | 1 | $30 |
| AstraZeneca | 1 | $30 |
| Perspectum Diagnostics Ltd | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $15 |
| Theratechnologies Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orbactiv$4,025
- DALVANCE$1,375
- ZEMDRI (PLAZOMICIN)$1,374
- DOVATO$247
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$156
- AVYCAZ$125
- TEFLARO$125
- NURTEC ODT$125
- NUZYRA$123
- ZERBAXA$120
- AJOVY$117
How this compares
$9,545 in reported general payments places this provider in the 85th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluconazole | 26 | $3,252 |
| Pyrazinamide | 14 | $1,208 |
| Doxycycline Hyclate | 48 | $903 |
| Doxycycline Monohydrate | 12 | $441 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $424 |
| Ciprofloxacin Hcl | 22 | $139 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $119 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in San Antonio
- Gregory AnsteadSan Antonio$171K
- David CheeSan Antonio$12K
- Thomas PattersonSan Antonio$11K
- Jeffrey JonesSan Antonio$11K
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.